With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cisplatin ...
(Web Desk) - The harmful effects of air pollution on health, including an increased risk of cancer, have been well-documented ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
Opioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the ...
Application error: a client-side exception has occurred (see the browser console for more information).
Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...
Bicara Therapeutics Inc. (BCAX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.Don't Miss our Black Friday ...